Engineered bacteria deliver cancer drug directly inside tumors in mice

Escherichia_coli_EMB

Source: Gene Drendel

New research suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice. Researchers used EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug with anti-tumor agents. 

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE